SG11201903911UA - Combinations of fgfr4 inhibitors and bile acid sequestrants - Google Patents
Combinations of fgfr4 inhibitors and bile acid sequestrantsInfo
- Publication number
- SG11201903911UA SG11201903911UA SG11201903911UA SG11201903911UA SG11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA
- Authority
- SG
- Singapore
- Prior art keywords
- basel
- klybeck
- novartis
- international
- bile acid
- Prior art date
Links
- 229920000080 bile acid sequestrant Polymers 0.000 title abstract 4
- 229940096699 bile acid sequestrants Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150082429 FGFR4 gene Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 2
- 229940125408 FGFR4 inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416222P | 2016-11-02 | 2016-11-02 | |
| PCT/IB2017/056787 WO2018083603A1 (en) | 2016-11-02 | 2017-11-01 | Combinations of fgfr4 inhibitors and bile acid sequestrants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903911UA true SG11201903911UA (en) | 2019-05-30 |
Family
ID=60661908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903911UA SG11201903911UA (en) | 2016-11-02 | 2017-11-01 | Combinations of fgfr4 inhibitors and bile acid sequestrants |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11229643B2 (zh) |
| EP (1) | EP3534902B1 (zh) |
| JP (2) | JP7394623B2 (zh) |
| KR (1) | KR102362648B1 (zh) |
| CN (2) | CN117257800A (zh) |
| AU (1) | AU2017354082B2 (zh) |
| BR (1) | BR112019008787A2 (zh) |
| CA (1) | CA3042475C (zh) |
| ES (1) | ES2934341T3 (zh) |
| IL (1) | IL266293B (zh) |
| MA (1) | MA46712A (zh) |
| MX (1) | MX2019005194A (zh) |
| PL (1) | PL3534902T3 (zh) |
| PT (1) | PT3534902T (zh) |
| RU (1) | RU2742033C2 (zh) |
| SG (1) | SG11201903911UA (zh) |
| WO (1) | WO2018083603A1 (zh) |
| ZA (1) | ZA201902744B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016054483A1 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| CN112759593A (zh) * | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007254005B2 (en) | 2006-02-10 | 2012-11-29 | Genentech, Inc. | Anti-FGF19 antibodies and methods using same |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| ZA200904573B (en) * | 2006-12-22 | 2010-09-29 | Ironwood Pharmaceuticals Inc | Compositions comprising bile acid sequestrants for treating esophageal disorders |
| TWI524898B (zh) | 2007-04-02 | 2016-03-11 | 建南德克公司 | 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ調節劑之用途 |
| US8524212B2 (en) * | 2007-10-24 | 2013-09-03 | Mitsubishi Tanabe Pharma Corporation | Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis |
| FR2933702A1 (fr) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| JP2012501637A (ja) | 2008-09-03 | 2012-01-26 | ライセンティア・リミテッド | Ｆｇｆｒ４に関連する癌細胞浸潤を抑制するための材料および方法 |
| US20100330175A1 (en) | 2009-06-24 | 2010-12-30 | Jobdevairakkam Christopher N | Cross-linked polyallylamine tablet core |
| MX342240B (es) | 2011-04-07 | 2016-09-21 | Genentech Inc | Anticuerpos anti-fgfr4 y metodos de uso. |
| US9708371B2 (en) | 2011-08-17 | 2017-07-18 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2014011900A2 (en) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibitors of the fibroblast growth factor receptor |
| KR20150104579A (ko) | 2012-12-27 | 2015-09-15 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 |
| WO2014105849A1 (en) | 2012-12-28 | 2014-07-03 | Xoma (Us) Llc | Antibodies specific for fgfr4 and methods of use |
| WO2014165287A1 (en) | 2013-03-12 | 2014-10-09 | The Translational Genomics Research Institute | Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4 |
| US9676792B2 (en) | 2013-03-15 | 2017-06-13 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| SG11201507478VA (en) | 2013-03-15 | 2015-10-29 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| AR097455A1 (es) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
| EP3057943B1 (en) | 2013-10-18 | 2018-04-25 | Eisai R&D Management Co., Ltd. | Pyrimidine fgfr4 inhibitors |
| JP6203954B2 (ja) | 2013-10-25 | 2017-09-27 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体 |
| WO2015107171A1 (en) | 2014-01-17 | 2015-07-23 | Sanofi | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody |
| AU2015277438B2 (en) * | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016023894A1 (en) | 2014-08-11 | 2016-02-18 | U3 Pharma Gmbh | Human anti-fgfr4 antibody |
| WO2016054483A1 (en) * | 2014-10-03 | 2016-04-07 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| WO2016064960A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| EP3259269B9 (en) | 2015-02-20 | 2020-03-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3273959A1 (en) * | 2015-03-25 | 2018-01-31 | Novartis Ag | Pharmaceutical combinations |
| EP3095465A1 (en) * | 2015-05-19 | 2016-11-23 | U3 Pharma GmbH | Combination of fgfr4-inhibitor and bile acid sequestrant |
-
2017
- 2017-11-01 WO PCT/IB2017/056787 patent/WO2018083603A1/en active Application Filing
- 2017-11-01 MX MX2019005194A patent/MX2019005194A/es unknown
- 2017-11-01 AU AU2017354082A patent/AU2017354082B2/en active Active
- 2017-11-01 EP EP17812269.3A patent/EP3534902B1/en active Active
- 2017-11-01 SG SG11201903911UA patent/SG11201903911UA/en unknown
- 2017-11-01 CN CN202311453574.XA patent/CN117257800A/zh active Pending
- 2017-11-01 CN CN201780068265.7A patent/CN109922804B/zh active Active
- 2017-11-01 PL PL17812269.3T patent/PL3534902T3/pl unknown
- 2017-11-01 KR KR1020197015424A patent/KR102362648B1/ko active IP Right Grant
- 2017-11-01 ES ES17812269T patent/ES2934341T3/es active Active
- 2017-11-01 PT PT178122693T patent/PT3534902T/pt unknown
- 2017-11-01 BR BR112019008787A patent/BR112019008787A2/pt unknown
- 2017-11-01 RU RU2019116061A patent/RU2742033C2/ru active
- 2017-11-01 US US16/347,194 patent/US11229643B2/en active Active
- 2017-11-01 MA MA046712A patent/MA46712A/fr unknown
- 2017-11-01 CA CA3042475A patent/CA3042475C/en active Active
- 2017-11-01 IL IL266293A patent/IL266293B/en unknown
- 2017-11-01 JP JP2019523704A patent/JP7394623B2/ja active Active
-
2019
- 2019-05-02 ZA ZA2019/02744A patent/ZA201902744B/en unknown
-
2021
- 2021-11-10 JP JP2021183688A patent/JP2022033766A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017354082B2 (en) | 2023-07-27 |
| BR112019008787A2 (pt) | 2019-07-16 |
| RU2019116061A (ru) | 2020-12-04 |
| MX2019005194A (es) | 2019-08-05 |
| AU2017354082A1 (en) | 2019-05-23 |
| JP7394623B2 (ja) | 2023-12-08 |
| MA46712A (fr) | 2019-09-11 |
| US20200261444A1 (en) | 2020-08-20 |
| ES2934341T3 (es) | 2023-02-21 |
| CA3042475A1 (en) | 2018-05-11 |
| KR20190082256A (ko) | 2019-07-09 |
| EP3534902B1 (en) | 2022-11-23 |
| PL3534902T3 (pl) | 2023-03-27 |
| CA3042475C (en) | 2024-01-16 |
| RU2019116061A3 (zh) | 2020-12-04 |
| IL266293A (en) | 2019-06-30 |
| PT3534902T (pt) | 2022-12-07 |
| US11229643B2 (en) | 2022-01-25 |
| EP3534902A1 (en) | 2019-09-11 |
| KR102362648B1 (ko) | 2022-02-11 |
| CN109922804A (zh) | 2019-06-21 |
| IL266293B (en) | 2022-07-01 |
| CN117257800A (zh) | 2023-12-22 |
| JP2019533701A (ja) | 2019-11-21 |
| RU2742033C2 (ru) | 2021-02-01 |
| CN109922804B (zh) | 2023-11-17 |
| ZA201902744B (en) | 2021-08-25 |
| JP2022033766A (ja) | 2022-03-02 |
| WO2018083603A1 (en) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901762WA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy |